Pub. Date : 2021 Feb
PMID : 32967046
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | The human monoclonal anti-fibroblast growth factor 23 (FGF23) antibody burosumab (KRN23) increases serum phosphate and improves bone turnover, fracture healing, pain, and physical function in XLH patients by inhibiting circulating FGF23; thus, burosumab is expected to be an effective treatment for TIO. | Phosphates | fibroblast growth factor 23 | Homo sapiens |
2 | The human monoclonal anti-fibroblast growth factor 23 (FGF23) antibody burosumab (KRN23) increases serum phosphate and improves bone turnover, fracture healing, pain, and physical function in XLH patients by inhibiting circulating FGF23; thus, burosumab is expected to be an effective treatment for TIO. | Phosphates | fibroblast growth factor 23 | Homo sapiens |